CXCR4/CXCL12 blockade therapy; a new horizon in TNBC therapy

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Triple-negative breast cancer (TNBC) is an aggressive subtype lacking targeted therapies, accounting for 15-20% of breast cancer cases.
• The tumor microenvironment (TME), comprising nonmalignant cells, extracellular matrix, and soluble factors like cytokines, significantly influences TNBC development and therapy resistance.
• Chemokines, such as the CXCL12/CXCR4 axis, are increasingly recognized for their critical roles in TNBC pathophysiology.

Purpose of the Study:

• To review the multifaceted role of the CXCR4/CXCL12 axis in triple-negative breast cancer.
• To elucidate the involvement of this axis in TNBC development, metastasis, angiogenesis, and acquired treatment resistance.
• To summarize current literature on targeting the CXCR4/CXCL12 axis for potential therapeutic interventions in TNBC.

Main Methods:

• Literature review synthesizing findings from preclinical and clinical studies.
• Analysis of the molecular mechanisms underlying CXCR4/CXCL12 signaling in TNBC.
• Compilation of data on therapeutic strategies targeting the CXCR4/CXCL12 axis.

Main Results:

• The CXCR4/CXCL12 axis is implicated in promoting TNBC cell proliferation and survival.
• This axis facilitates tumor angiogenesis and the formation of a pro-metastatic microenvironment.
• CXCR4/CXCL12 signaling contributes to resistance against various cancer therapies.

Conclusions:

• The CXCR4/CXCL12 axis is a critical regulator of TNBC progression and therapeutic response.
• Targeting the CXCR4/CXCL12 axis represents a promising strategy for developing novel treatments for TNBC.
• Further research into this axis may uncover new therapeutic targets and combination strategies for improved patient outcomes.